Education
About Us
Working with TipRanks
Follow Us
Pds Biotechnology (PDSB)
:PDSB
Earnings Data
Report Date
Aug 13, 2025TBA Not Confirmed
Period Ending
2025 (Q2)Consensus EPS Forecast
-0.24Last Year’s EPS
-0.23Same Quarter Last Year
Strong Buy
Based on 3 Analysts Ratings
---
Earnings Call Summary
Earnings Call Date:May 14, 2025
|% Change Since: 11.81%
|Next Earnings Date:Aug 13, 2025
Earnings Call Sentiment|Positive
The earnings call presents a positive outlook with significant progress in clinical trials, especially with the initiation of the VERSATILE 003 Phase 3 trial and promising Phase 2 results. Financial metrics show improvement, but operational costs and cash flow remain challenges.Company Guidance
In the first quarter of 2025, PDS Biotech reported a net loss of approximately $8.5 million, translating to $0.21 per basic and diluted share, compared to $10.6 million or $0.30 per share in the same period of 2024. This improvement was primarily driven by increased tax benefits and reduced operating expenses, with research and development costs decreasing from $6.7 million to $5.8 million, and general administrative expenses slightly decreasing to $3.3 million. Total operating expenses were $9.1 million, down from $10.1 million the previous year. The company ended the quarter with a cash balance of $40 million, down from $41.7 million at the end of 2024. Additionally, PDS Biotech successfully raised $11 million through a securities purchase agreement and completed a debt refinancing to extend the term by 36 months, with the first four months being interest-only.Initiation of VERSATILE 003 Phase 3 Trial
PDS Biotech initiated the VERSATILE 003 Phase 3 clinical trial for Versamune HPV plus pembrolizumab, targeting HPV16-positive head and neck cancer. The trial design has been approved by the FDA and includes 350 patients.
Positive Phase 2 VERSATILE 002 Results
The VERSATILE 002 trial showed encouraging patient survival and clinical responses, with a median overall survival of 30 months compared to the standard 12 months for HPV16-positive head and neck cancer.
FDA IND Clearance for New Drug
FDA cleared the investigational new drug application for Versamune MUC1 and IL-12 fused antibody drug conjugate PDS01ADC for metastatic colorectal cancer.
Strong Financial Position
Reported a net loss of $8.5 million, an improvement from the previous year's $10.6 million. Cash balance stood at $40 million as of March 31, 2025.
---
PDSB Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
---
PDSB Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
May 14, 2025 | $1.27 | $1.31 | +3.15% |
Mar 27, 2025 | $1.24 | $1.25 | +0.81% |
Nov 14, 2024 | $2.76 | $2.25 | -18.48% |
Aug 13, 2024 | $3.05 | $3.05 | 0.00% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
---
FAQ
When does Pds Biotechnology (PDSB) report earnings?
Pds Biotechnology (PDSB) is schdueled to report earning on Aug 13, 2025, TBA Not Confirmed.
What is Pds Biotechnology (PDSB) earnings time?
Pds Biotechnology (PDSB) earnings time is at Aug 13, 2025, TBA Not Confirmed.
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is PDSB EPS forecast?
PDSB EPS forecast for the fiscal quarter 2025 (Q2) is -0.24.
---